Skip to content

Advertisement

  • Correction
  • Open Access

Correction to: Metformin improved health-related quality of life in ethnic Chinese women with polycystic ovary syndrome

Health and Quality of Life Outcomes201816:217

https://doi.org/10.1186/s12955-018-1026-4

  • Received: 3 October 2018
  • Accepted: 3 October 2018
  • Published:

The original article was published in Health and Quality of Life Outcomes 2016 14:119

Correction

The original article [1] contains a number of statements that the authors would like to be disregarded, noted ahead:
  1. 1)
    In the Methods section, along with the references mentioned in the statement:

    ‘In order to account for the effect of medication behavior, the Morisky 8-item medication adherence scale (MMAS-8) [30] was applied to measure medication adherence. The MMAS-8 is one of the most commonly used self-report adherence questionnaires. The Chinese version of MMAS-8 has been validated among a convenience sample of 176 patients in China [31]. The scale showed acceptable internal consistency (Cronbach’s α = 0.77) and test-retest reliability (r = 0.88), and good construct validity.’

     
  2. 2)
    In the respective captions of Tables 3 and 4:

    ‘The analysis was adjusted for the effect of medication adherence via the Morisky 8-item medication adherence scale’.

     
Table 3

Mixed effect model analysis of metformin effect on general HRQoL outcome measured via WHOQOL-Bref

WHOQOL-Bref

Total

Coefficient (SE)

Subgroups

Normal weight

Coefficient (SE)

Overweight

Coefficient (SE)

Non- hyperandrogenism

Coefficient (SE)

Hyperandrogenism

Coefficient (SE)

Total scores

 Treatment time

     

  Visit 2 (reference = visit 1)

−0.93 (1.04)

0.47 (0.77)

−1.72 (1.44)

1.49 (1.26)

0.79 (0.56)

  Visit 3 (reference = visit 1)

0.06 (0.94)

0.07 (0.75)

−0.27 (1.45)

0.52 (1.30)

0.70 (0.56)

Physical domain

 Treatment time

p = 0.010

 

p = 0.036

 

p = 0.015

  Visit 2 (reference = visit 1)

0.58 (0.20)*

0.50 (0.29)

0.57 (0.28)*

0.62 (0.50)

0.55 (0.22)*

  Visit 3 (reference = visit 1)

0.54 (0.20)*

0.50 (0.29)

0.64 (0.27)*

0.29 (0.51)

0.60 (0.22)*

Psychological domain

 Treatment time

     

  Visit 2 (reference = visit 1)

−0.90 (0.06)

−0.17 (0.34)

−1.49 (0.57)

0.63 (0.58)

−0.16 (0.23)

  Visit 3 (reference = visit 1)

−0.06 (0.39)

−0.14 (0.33)

−0.76 (0.57)

0.17 (0.60)

0.002 (0.23)

Social domain

 Treatment time

     

  Visit 2 (reference = visit 1)

−0.61 (0.39)

0.10 (0.31)

0.18 (0.24)

−0.83 (0.69)

0.05 (0.21)

  Visit 3 (reference = visit 1)

−0.31 (0.35)

−0.31 (0.30)

0.14 (0.25)

−0.02 (0.63)

−0.14 (0.21)

Environment domain

 Treatment time

     

  Visit 2 (reference = visit 1)

0.13 (0.15)

−0.07 (0.23)

0.29 (0.21)

−0.34 (0.27)

0.23 (0.18)

  Visit 3 (reference = visit 1)

0.07 (0.16)

−0.06 (0.22)

0.17 (0.22)

−0.16 (0.28)

0.10 (0.18)

Note: Visit 1 is 1st office visit when patients were diagnosed with PCOS (baseline). Once PCOS was diagnosed, patients started metformin treatment. Visit 2 was 2nd office visit (1st-2nd month of treatment). Visit 3 was 3rd office visit (3rd- 4th month of treatment). The analysis was adjusted for the effect of medication adherence via the Morisky 8-item medication adherence scale

Abbreviations: HRQoL health-related quality of life, SE standard error

*p < 0.05

Table 4

Mixed effect model analysis of metformin effect on PCOS-specific HRQoL measured via Chi-PCOSQ

Chi-PCOSQ

Total

Coefficient (SE)

Subgroups

Normal weight

Coefficient (SE)

Overweight

Coefficient (SE)

Non- hyperandrogenism

Coefficient (SE)

Hyperandrogenism

Coefficient (SE)

Total scores

 Treatment time

     

  Visit 2 (reference = visit 1)

0.44 (0.56)

0.75 (0.86)

0.20 (0.75)

−0.58 (0.89)

0.61 (0.66)

  Visit 3 (reference = visit 1)

1.25 (0.56)

1.77 (0.84)

0.80 (0.78)

0.11 (0.92)

1.45 (0.66)*

Weight domain

 Treatment time

     

  Visit 2 (reference = visit 1)

−0.06 (0.14)

0.11 (0.22)

−0.18 (0.19)

−0.04 (0.28)

−0.07 (0.17)

  Visit 3 (reference = visit 1)

0.12 (0.15)

0.15 (0.21)

0.10 (0.20)

−0.01 (0.29)

0.15 (0.17)

Infertility domain

 Treatment time

p = 0.043

   

p = 0.048

  Visit 2 (reference = visit 1)

0.25 (0.18)

0.34 (0.23)

0.15 (0.29)

−0.06 (0.33)

0.32 (0.21)

  Visit 3 (reference = visit 1)

0.46 (0.18)*

0.34 (0.24)

0.59 (0.28)*

0.12 (0.34)

0.52 (0.21)*

Menstrual domain

 Treatment time

     

  Visit 2 (reference = visit 1)

0.10 (0.18)

0.21 (0.29)

0.02 (0.24)

0.26 (0.39)

0.08 (0.20)

  Visit 3 (reference = visit 1)

0.19 (0.18)

0.36 (0.27)

0.04 (0.25)

0.58 (0.41)

0.11 (0.20)

Emotions domain

 Treatment time

     

  Visit 2 (reference = visit 1)

0.07 (0.15)

0.15 (0.21)

0.01 (0.21)

0.82 (0.33)*

0.04 (0.18)

  Visit 3 (reference = visit 1)

0.14 (0.15)

0.30 (0.21)

0.003 (0.21)

0.43 (0.29)

0.13 (0.18)

Body hair domain

 Treatment time

     

  Visit 2 (reference = visit 1)

0.03 (0.14)

0.18 (0.19)

−0.08 (0.20)

−0.34 (0.20)

0.10 (0.17)

  Visit 3 (reference = visit 1)

0.02 (0.14)

0.24 (0.18)

−0.16 (0.21)

−0.37 (0.21)

0.10 (0.17)

Acne & Hair loss domain

 Treatment time

p = 0.008

 

p = 0.043

 

p = 0.007

  Visit 2 (reference = visit 1)

−0.51 (0.28)

−0.10 (0.19)

0.01 (0.20)

−0.46 (0.18)*

−0.55 (0.35)

  Visit 3 (reference = visit 1)

0.45 (0.26)

0.08 (0.19)

0.33 (0.21)

−0.28 (0.19)

0.71 (0.32)*

Note: Visit 1 is 1st office visit when patients were diagnosed with PCOS (baseline). Once PCOS was diagnosed, patients started metformin treatment. Visit 2 was 2nd office visit (1st-2nd month of treatment). Visit 3 was 3rd office visit (3rd- 4th month of treatment). The analysis was adjusted for the effect of medication adherence via the Morisky 8-item medication adherence scale

Abbreviations: PCOS polycystic ovary syndrome, HRQoL Health related Quality of life, SE standard error

*p < 0.05

These statements as well as the references contained within them are to be disregarded as it was discovered that the patients included in the analyses did not receive the MMAS and thus, the analyses did not adjust for the MMAS scores (as was erroneously asserted in the original text).

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, 1 University Road, Tainan, 7010, Taiwan
(2)
Department of Obstetrics and Gynecology, College of Medicine, National Cheng Kung University and Hospital, Tainan, Taiwan
(3)
Department of Rehabilitation Sciences, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Hong Kong

Reference

  1. Ou H-T, et al. Metformin improved health-related quality of life in ethnic Chinese women with polycystic ovary syndrome. Health Qual Life Outcomes. 2016;14(119) https://doi.org/10.1186/s12955-016-0520-9.

Copyright

© The Author(s). 2018

Advertisement